Luseogliflozin is a potent and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes mellitus by promoting urinary glucose excretion, thereby lowering blood glucose levels. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include lusefi and luseogliflozinum. Its PubChem CID is 11988953.
Luseogliflozin
| CAS No | 898537-18-3 |
|---|---|
| Molecular Formula | C23H30O6S |
| Molecular Weight | 434.50 g/mol |
| Synonyms | (2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Luseogliflozin is a potent and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes mellitus by promoting urinary glucose excretion, thereby lowering blood glucose levels.
The listed CAS number is 898537-18-3.
The listed molecular formula is C23H30O6S.
The listed molecular weight is 434.50 g/mol.
(2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol.
The source lists lusefi and luseogliflozinum.